Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
US5856329A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jun 28, 1995 |
| Grant date | Jan 5, 1999 |
| Priority date | — |
| Expiry date | Jun 28, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method according to which neuroprotection is conferred upon ocular nerve cells by administration of a drug of formula I to the optic nerve and/or retina of a mammal within a period prior to or following an insult to ocular nerve cells but prior to cell death ##STR1## wherein the 2-imidazolin-2-ylamino group may be in either the 5- or 6-position of the quinoxaline nucleus; x, y and z may be in any of the remaining 5-, 6-, 7- or 8-positions and are selected from hydrogen, halogen, lower alkyl, lower alkoxy or trifluoromethyl; and R is an optional substitutent in either the 2- or 3-position of the quinoxaline nucleus and may be hydrogen, lower alkyl or lower alkoxy is disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.